<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35296227</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine.</ArticleTitle>
        <Pagination>
          <StartPage>2029259</StartPage>
          <MedlinePgn>2029259</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2029259</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2029259</ELocationID>
        <Abstract>
          <AbstractText>Whether telbivudine (LdT) treatment to pregnant women with hepatitis B surface antigen (HBsAg) affects infant immune response to hepatitis B vaccine (HepB) has not been investigated. A total of 127 HBsAg positive mothers and their neonates were enrolled and followed up at 11-13 months. Mothers took LdT (LdT group) or did not receive antiviral therapy (control group). Infant anti-HBs, immune cells and cytokines were measured after HepB was administered according to 0-1-6 procedure. We performed a 1:3 propensity score matching (PSM). Immune indexes in the two groups were compared. Baseline characteristics of mother-baby pairs were comparable in LdT group and control group. Infant anti-HBs geometric mean concentration (GMC) did not differ significantly between the two groups [767.70 (745.35) vs. 711.90 (819.60), <i>P</i> = .599]. There was no difference between the two groups in infant positive rate of anti-HBs [97.8% (91/93) vs. 97.1% (33/34), <i>P</i> = .999] and strong positive rate of anti-HBs [40.9% (38/93) vs. 44.1% (15/34), <i>P</i> = .742]. Infants with negative, low, medium, and high anti-HBs levels were similarly distributed between the two groups (<i>P</i> = .511). No differences in proportion of helper T cells, cytotoxic T cells, B cells, myeloid dendritic cells, and plasmacytoid dendritic cells of infants (<i>P</i> &gt; .05) were detected between the two groups. Children in the LdT and control group had comparable levels of interleukin-2, interleukin-4, interleukin-6, interleukin-10, interleukin-12, interferon-α, interferon-γ and tumor necrosis factor-α (<i>P</i> &gt; .05). Intrauterine exposure to LdT was safe to infant immune response to HepB after birth.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yandi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Wenxin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Cong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Shuying</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yongliang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Suping</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2OC4HKD3SF</RegistryNumber>
          <NameOfSubstance UI="D000077712">Telbivudine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006509" MajorTopicYN="Y">Hepatitis B</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018445" MajorTopicYN="N">Infectious Disease Transmission, Vertical</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077712" MajorTopicYN="N">Telbivudine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Immune response</Keyword>
        <Keyword MajorTopicYN="Y">hepatitis B vaccine</Keyword>
        <Keyword MajorTopicYN="Y">prenatal exposure</Keyword>
        <Keyword MajorTopicYN="Y">propensity score matching</Keyword>
        <Keyword MajorTopicYN="Y">telbivudine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35296227</ArticleId>
        <ArticleId IdType="pmc">PMC8993090</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2022.2029259</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Global progress report on HIV, viral hepatitis and sexually transmitted infections. World Health Organization; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Lavanchy D.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis. 2004;11(2):97–6. doi:10.1046/j.1365-2893.2003.00487.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2893.2003.00487.x</ArticleId>
            <ArticleId IdType="pubmed">14996343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CGY, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunization in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis. BMJ. 2006;332:332. doi:10.1136/bmj.38726.404120.7C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.38726.404120.7C</ArticleId>
            <ArticleId IdType="pmc">PMC1363909</ArticleId>
            <ArticleId IdType="pubmed">16443611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Lin L, Hu F, Lee J, Lin W, Yang Y, Huang F, Wu S, Chen SC, Wen W, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773–781.e772. doi:10.1053/j.gastro.2011.12.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2011.12.035</ArticleId>
            <ArticleId IdType="pubmed">22198276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen W, Chang M, Zhao L, Ni Y-H, Hsu H-Y, Wu J-F, Chen P-J, Chen D-S, Chen H-L. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59(1):24–30. doi:10.1016/j.jhep.2013.02.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2013.02.015</ArticleId>
            <ArticleId IdType="pubmed">23485519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepatitis. 2012;19(2):e18–25. doi:10.1111/j.1365-2893.2011.01492.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2893.2011.01492.x</ArticleId>
            <ArticleId IdType="pubmed">22239517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funk A, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, Chou R, Bulterys M, Shimakawa Y. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84. doi:10.1016/S1473-3099(20)30586-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(20)30586-7</ArticleId>
            <ArticleId IdType="pubmed">32805200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terrault N, Lok A, McMahon B, Chang K-M, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. doi:10.1002/hep.29800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29800</ArticleId>
            <ArticleId IdType="pmc">PMC5975958</ArticleId>
            <ArticleId IdType="pubmed">29405329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C, Duan Z, Bhamidimarri K, Zou H, Liang X, Li J, Tong MJ. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10(5):452–59. doi:10.1016/j.cgh.2011.10.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2011.10.041</ArticleId>
            <ArticleId IdType="pubmed">22079509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liver. EAftSot . EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. doi:10.1016/j.jhep.2017.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.03.021</ArticleId>
            <ArticleId IdType="pubmed">28427875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C, Li M, Zeng H, Zhang Y, Cao W-H, Wang Y, Zhou M-F, Hu Y-H, Wan G, Xie Y, et al. Developmental consequences of prenatal telbivudine exposure during the third trimester. Clin Gastroenterol Hepatol. 2021;19(5):1061–63. doi:10.1016/j.cgh.2020.04.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2020.04.056</ArticleId>
            <ArticleId IdType="pubmed">32371166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Nan Y. Telbivudine induced neutropenia in a patient with chronic hepatitis B: a case report. J Clin Hepatobiliary Dis. 2015;31:273–273.</Citation>
        </Reference>
        <Reference>
          <Citation>Bridges E, Selden J, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother. 2008;52(7):2521–28. doi:10.1128/aac.00029-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.00029-08</ArticleId>
            <ArticleId IdType="pmc">PMC2443876</ArticleId>
            <ArticleId IdType="pubmed">18474576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia J, Li L. Guidelines for prevention and treatment of chronic hepatitis B (2010 China). J Pract Liver Dis. 2011;1:7–21.</Citation>
        </Reference>
        <Reference>
          <Citation>McDonald R, McDonald J, Kallmes D, Carter R, Behind the numbers: propensity score analysis-a primer for the diagnostic radiologist. Radiology. Radiology. 2013;269(3):640–645. doi:10.1148/radiol.13131465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.13131465</ArticleId>
            <ArticleId IdType="pubmed">24261493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56:S112–122. doi:10.1016/S0168-8278(12)60012-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0168-8278(12)60012-9</ArticleId>
            <ArticleId IdType="pubmed">22300461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng C, Chien R, Liaw Y. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57(2):442–50. doi:10.1016/j.jhep.2012.02.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2012.02.033</ArticleId>
            <ArticleId IdType="pubmed">22504333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giles M, Visvanathan K, Sasadeusz J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. Antivir Ther. 2011;16(5):621–28. doi:10.3851/imp1813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3851/imp1813</ArticleId>
            <ArticleId IdType="pubmed">21817183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nachega J, Uthman O, Mofenson L, Anderson JR, Kanters S, Renaud F, Ford N, Essajee S, Doherty MC, Mills EJ, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-Infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;76(1):1–12. doi:10.1097/qai.0000000000001359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/qai.0000000000001359</ArticleId>
            <ArticleId IdType="pmc">PMC5553236</ArticleId>
            <ArticleId IdType="pubmed">28291053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han G, Cao M, Zhao W, Jiang H-X, Wang C-M, Bai S-F, Yue X, Wang G-J, Tang X, Fang Z-X, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55(6):1215–21. doi:10.1016/j.jhep.2011.02.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2011.02.032</ArticleId>
            <ArticleId IdType="pubmed">21703206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao T, Shao Z, Wu L, Dong S, Gao L, Wu Y, Shi X, Shi J, Liu G, Wang J, et al. Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: a 3-year follow-up study in China. Vaccine. 2021;39(18):2537–44. doi:10.1016/j.vaccine.2021.03.074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.03.074</ArticleId>
            <ArticleId IdType="pubmed">33814231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang X, Liu P, He Z, Chen X, and Xiao X. The effect of maternal use of telbivudine on neonatal CD4+CD25+ regulatory T cells for the prevention of mother-to-child transmission of hepatitis B virus. Clinics and Research in Hepatology and Gastroenterology. 2020; 44(2):195–203. doi:10.1016/j.clinre.2019.06.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinre.2019.06.004</ArticleId>
            <ArticleId IdType="pubmed">31257091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho C, Chang T, Chien R. Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis. PloS One. 2019;14(11):e0225482. doi:10.1371/journal.pone.0225482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0225482</ArticleId>
            <ArticleId IdType="pmc">PMC6879168</ArticleId>
            <ArticleId IdType="pubmed">31770396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Pan C, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60(2):468–76. doi:10.1002/hep.27034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27034</ArticleId>
            <ArticleId IdType="pmc">PMC4282428</ArticleId>
            <ArticleId IdType="pubmed">25187919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C, Han G, Jiang H, Zhao W, Cao M, Wang C, Yue X, Wang G. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10(5):520–26. doi:10.1016/j.cgh.2012.01.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2012.01.019</ArticleId>
            <ArticleId IdType="pubmed">22343511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han G, Jiang H, Wang C, Ding Y, Wang G-J, Yue X, Zhou L, Zhao W. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat. 2017;24(6):514–21. doi:10.1111/jvh.12670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jvh.12670</ArticleId>
            <ArticleId IdType="pubmed">28039902</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35296227</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine.</ArticleTitle>
        <Pagination>
          <StartPage>2029259</StartPage>
          <MedlinePgn>2029259</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">2029259</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2022.2029259</ELocationID>
        <Abstract>
          <AbstractText>Whether telbivudine (LdT) treatment to pregnant women with hepatitis B surface antigen (HBsAg) affects infant immune response to hepatitis B vaccine (HepB) has not been investigated. A total of 127 HBsAg positive mothers and their neonates were enrolled and followed up at 11-13 months. Mothers took LdT (LdT group) or did not receive antiviral therapy (control group). Infant anti-HBs, immune cells and cytokines were measured after HepB was administered according to 0-1-6 procedure. We performed a 1:3 propensity score matching (PSM). Immune indexes in the two groups were compared. Baseline characteristics of mother-baby pairs were comparable in LdT group and control group. Infant anti-HBs geometric mean concentration (GMC) did not differ significantly between the two groups [767.70 (745.35) vs. 711.90 (819.60), <i>P</i> = .599]. There was no difference between the two groups in infant positive rate of anti-HBs [97.8% (91/93) vs. 97.1% (33/34), <i>P</i> = .999] and strong positive rate of anti-HBs [40.9% (38/93) vs. 44.1% (15/34), <i>P</i> = .742]. Infants with negative, low, medium, and high anti-HBs levels were similarly distributed between the two groups (<i>P</i> = .511). No differences in proportion of helper T cells, cytotoxic T cells, B cells, myeloid dendritic cells, and plasmacytoid dendritic cells of infants (<i>P</i> &gt; .05) were detected between the two groups. Children in the LdT and control group had comparable levels of interleukin-2, interleukin-4, interleukin-6, interleukin-10, interleukin-12, interferon-α, interferon-γ and tumor necrosis factor-α (<i>P</i> &gt; .05). Intrauterine exposure to LdT was safe to infant immune response to HepB after birth.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yandi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Wenxin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Cong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Shuying</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yongliang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Suping</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2OC4HKD3SF</RegistryNumber>
          <NameOfSubstance UI="D000077712">Telbivudine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006509" MajorTopicYN="Y">Hepatitis B</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018445" MajorTopicYN="N">Infectious Disease Transmission, Vertical</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077712" MajorTopicYN="N">Telbivudine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Immune response</Keyword>
        <Keyword MajorTopicYN="Y">hepatitis B vaccine</Keyword>
        <Keyword MajorTopicYN="Y">prenatal exposure</Keyword>
        <Keyword MajorTopicYN="Y">propensity score matching</Keyword>
        <Keyword MajorTopicYN="Y">telbivudine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35296227</ArticleId>
        <ArticleId IdType="pmc">PMC8993090</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2022.2029259</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Global progress report on HIV, viral hepatitis and sexually transmitted infections. World Health Organization; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Lavanchy D.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis. 2004;11(2):97–6. doi:10.1046/j.1365-2893.2003.00487.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2893.2003.00487.x</ArticleId>
            <ArticleId IdType="pubmed">14996343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CGY, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunization in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis. BMJ. 2006;332:332. doi:10.1136/bmj.38726.404120.7C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.38726.404120.7C</ArticleId>
            <ArticleId IdType="pmc">PMC1363909</ArticleId>
            <ArticleId IdType="pubmed">16443611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Lin L, Hu F, Lee J, Lin W, Yang Y, Huang F, Wu S, Chen SC, Wen W, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773–781.e772. doi:10.1053/j.gastro.2011.12.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2011.12.035</ArticleId>
            <ArticleId IdType="pubmed">22198276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen W, Chang M, Zhao L, Ni Y-H, Hsu H-Y, Wu J-F, Chen P-J, Chen D-S, Chen H-L. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59(1):24–30. doi:10.1016/j.jhep.2013.02.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2013.02.015</ArticleId>
            <ArticleId IdType="pubmed">23485519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepatitis. 2012;19(2):e18–25. doi:10.1111/j.1365-2893.2011.01492.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2893.2011.01492.x</ArticleId>
            <ArticleId IdType="pubmed">22239517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funk A, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, Chou R, Bulterys M, Shimakawa Y. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84. doi:10.1016/S1473-3099(20)30586-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(20)30586-7</ArticleId>
            <ArticleId IdType="pubmed">32805200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terrault N, Lok A, McMahon B, Chang K-M, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. doi:10.1002/hep.29800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29800</ArticleId>
            <ArticleId IdType="pmc">PMC5975958</ArticleId>
            <ArticleId IdType="pubmed">29405329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C, Duan Z, Bhamidimarri K, Zou H, Liang X, Li J, Tong MJ. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10(5):452–59. doi:10.1016/j.cgh.2011.10.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2011.10.041</ArticleId>
            <ArticleId IdType="pubmed">22079509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liver. EAftSot . EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. doi:10.1016/j.jhep.2017.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2017.03.021</ArticleId>
            <ArticleId IdType="pubmed">28427875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C, Li M, Zeng H, Zhang Y, Cao W-H, Wang Y, Zhou M-F, Hu Y-H, Wan G, Xie Y, et al. Developmental consequences of prenatal telbivudine exposure during the third trimester. Clin Gastroenterol Hepatol. 2021;19(5):1061–63. doi:10.1016/j.cgh.2020.04.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2020.04.056</ArticleId>
            <ArticleId IdType="pubmed">32371166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Nan Y. Telbivudine induced neutropenia in a patient with chronic hepatitis B: a case report. J Clin Hepatobiliary Dis. 2015;31:273–273.</Citation>
        </Reference>
        <Reference>
          <Citation>Bridges E, Selden J, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother. 2008;52(7):2521–28. doi:10.1128/aac.00029-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.00029-08</ArticleId>
            <ArticleId IdType="pmc">PMC2443876</ArticleId>
            <ArticleId IdType="pubmed">18474576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia J, Li L. Guidelines for prevention and treatment of chronic hepatitis B (2010 China). J Pract Liver Dis. 2011;1:7–21.</Citation>
        </Reference>
        <Reference>
          <Citation>McDonald R, McDonald J, Kallmes D, Carter R, Behind the numbers: propensity score analysis-a primer for the diagnostic radiologist. Radiology. Radiology. 2013;269(3):640–645. doi:10.1148/radiol.13131465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.13131465</ArticleId>
            <ArticleId IdType="pubmed">24261493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56:S112–122. doi:10.1016/S0168-8278(12)60012-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0168-8278(12)60012-9</ArticleId>
            <ArticleId IdType="pubmed">22300461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng C, Chien R, Liaw Y. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57(2):442–50. doi:10.1016/j.jhep.2012.02.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2012.02.033</ArticleId>
            <ArticleId IdType="pubmed">22504333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giles M, Visvanathan K, Sasadeusz J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. Antivir Ther. 2011;16(5):621–28. doi:10.3851/imp1813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3851/imp1813</ArticleId>
            <ArticleId IdType="pubmed">21817183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nachega J, Uthman O, Mofenson L, Anderson JR, Kanters S, Renaud F, Ford N, Essajee S, Doherty MC, Mills EJ, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-Infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;76(1):1–12. doi:10.1097/qai.0000000000001359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/qai.0000000000001359</ArticleId>
            <ArticleId IdType="pmc">PMC5553236</ArticleId>
            <ArticleId IdType="pubmed">28291053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han G, Cao M, Zhao W, Jiang H-X, Wang C-M, Bai S-F, Yue X, Wang G-J, Tang X, Fang Z-X, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55(6):1215–21. doi:10.1016/j.jhep.2011.02.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2011.02.032</ArticleId>
            <ArticleId IdType="pubmed">21703206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao T, Shao Z, Wu L, Dong S, Gao L, Wu Y, Shi X, Shi J, Liu G, Wang J, et al. Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: a 3-year follow-up study in China. Vaccine. 2021;39(18):2537–44. doi:10.1016/j.vaccine.2021.03.074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2021.03.074</ArticleId>
            <ArticleId IdType="pubmed">33814231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang X, Liu P, He Z, Chen X, and Xiao X. The effect of maternal use of telbivudine on neonatal CD4+CD25+ regulatory T cells for the prevention of mother-to-child transmission of hepatitis B virus. Clinics and Research in Hepatology and Gastroenterology. 2020; 44(2):195–203. doi:10.1016/j.clinre.2019.06.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinre.2019.06.004</ArticleId>
            <ArticleId IdType="pubmed">31257091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho C, Chang T, Chien R. Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis. PloS One. 2019;14(11):e0225482. doi:10.1371/journal.pone.0225482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0225482</ArticleId>
            <ArticleId IdType="pmc">PMC6879168</ArticleId>
            <ArticleId IdType="pubmed">31770396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Pan C, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60(2):468–76. doi:10.1002/hep.27034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27034</ArticleId>
            <ArticleId IdType="pmc">PMC4282428</ArticleId>
            <ArticleId IdType="pubmed">25187919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan C, Han G, Jiang H, Zhao W, Cao M, Wang C, Yue X, Wang G. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10(5):520–26. doi:10.1016/j.cgh.2012.01.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2012.01.019</ArticleId>
            <ArticleId IdType="pubmed">22343511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han G, Jiang H, Wang C, Ding Y, Wang G-J, Yue X, Zhou L, Zhao W. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat. 2017;24(6):514–21. doi:10.1111/jvh.12670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jvh.12670</ArticleId>
            <ArticleId IdType="pubmed">28039902</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
